Rocketaf is the first phase iii study assessing the use of rivaroxaban for stroke. Rocketaf rivaroxaban once daily oral direct factor xa. The study took place at 1 178 sites in 45 countries. Subgroup analyses show consistent benefits of rivaroxaban. As in any controlled trial, the results are only as good as the quality of treatment in the control arm. A prespecified analysis of the rocket af trial3 rivaroxaban once. Ingelheim, daiichi sankyo, pfizer, portola, csl behring and medscape.
Adverse outcomes related to major bleeding similar. Patients n1,280 with nonvalvular af at increased risk for stroke were. The rocket af study was a blinded, doubledummy, randomizedcontrolled trial in which 14,262 patients with nonvalvular af at increased risk for stroke were assigned to rivaroxaban 20 mg daily or. Rocket af rivaroxaban once daily oral direct factor xa inhibition compared with vitamin kantagonism for prevention of stroke and embolism trial in atrialfibrillation was a prospective, randomized, doubleblind, doubledummy parallel group outcomes study comparing oncedaily rivaroxaban 20 mg, or 15 mg for patients with. Rivaroxaban for stroke prevention in east asian patients. Personalized management of atrial fibrillation medpage today. Rocketaf, 2010 trial summary pdf trial summary a randomised clinical trial investigating the effect of rivaroxaban versus warfarin standard dose in subjects with nonvalvular atrial fibrillation. Note that the rate of strokes and blood clots was not different if either rivaroxaban or warfarin was discontinued temporarily or permanently during the trial period. London, uk the key rocket af trial used a faulty pointofcare device to measure inr in its comparator arm of patients taking warfarin, which may have made warfarin results look worse than. Comparison of rely and rocket af trial designs and outcomes comparison of study designs. Validity of pivotal rocket af rivaroxaban trial questioned.
Protocol this trial protocol has been provided by the authors to give readers additional information about their work. Atrial fibrillation af is a major risk factor for disabling ischemic stroke due to embolism from the left atrial appendage. An efficacy and safety study of rivaroxaban with warfarin. Engage af timi 48 trial those with crcl rocket af trial consult package inserts for specific usedosing recommendations with concomitant cyp3a4 andor pgp inducers or inhibitors. A comparison of the rely and rocket af trials wikidoc. The rocket af trial directly compared the safety and efficacy of rivaroxaban and warfarin for stroke prevention and was the major trial to firmly establish and enable the use of rivaroxaban in patients with af around the globe. Antiarrhythmic and doac dosing in obesity medpage today. Also, it should be noted how in both the rely and rocket af trials, the fda raised some question on whether warfarin was used in an appropriate way.
Apixaban vs warfarin in patients with atrial fibrillation 1 apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation. Briefly, the rocket af was a multicenter, randomized, doubleblind, doubledummy, eventdriven trial comparing fixeddose rivaroxaban 20 mg daily or 15 mg daily in patients with creatinine clearance of 30 to 49 mlmin with adjusteddose warfarin target international normalized ratio inr. Pointofcare warfarin monitoring in the rocket af trial. The prevalence of af increases with increasing age fig. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation aristotle trial. To address a lack of comparability between trial populations caused by the restriction of rocket af to high risk patients, we conducted a subgroup analysis in patients with a chads 2 score.
Apixaban versus warfarin in patients with atrial fibrillation. A separate trial, j rocket af, compared the safety of a japanspecific rivaroxaban dose with warfarin administered according to japanese guidelines in japanese patients with af. The rivaroxaban once daily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation rocket af was a multicenter. A rocket af trial subgroup analysis presented at the 2012 international stroke conference confirmed in the itt population that rivaroxaban treatment was a significant negative predictor of ich compared with warfarin hr. Anticoagulation feasible when renal disease gets worse. The trial was designed to determine whether rivaroxaban was. Of the 39,052 patients taking xarelto in pmss, the incidence of major bleeding was observed at 2.
Rivaroxaban for stroke prevention in atrial fibrillation. New global realworld data from atrial fibrillation studies. The pioneer af pci trial is the largest rct n2124 to date comparing triple therapy with. Rocket af rivaroxaban once daily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation, published in the new england journal of medicine in 2011, demonstrated the noninferiority of rivaroxaban compared with warfarin for the primary prevention of stroke or. The rivaroxaban once daily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation rocket af was published in 2011. Af is the first phase iii study assessing the use of rivaroxaban for stroke prevention in af patients. Clinical characteristics and outcomes participating in the. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. Trial in atrial fibrillation rocket af,6 apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation aristotle,7 and the engage af timi 48 study edoxaban. The rocket af rivaroxaban oncedaily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation study was a randomized controlled trial of rivaroxaban versus warfarin for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Atrial fibrillation must be documented by ecg evidence e. Rocket af investigators seek to calm concerns about trial reliability december, 2015 new questions raised about rocket af, pivotal xarelto trial. Efficacy and safety of rivaroxaban in patients with diabetes and. In this noninferiority trial, we randomly assigned 18,1 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran110 mg or 150 mg.
The design of the rocket af study has been previously described. Rivaroxaban once daily oral direct factor xa inhibition. Rivaroxaban vs warfarin in patients with atrial fibrillation 1 rivaroxaban once daily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in af. We found no statistically significant efficacy differences among the three drugs, although apixaban and dabigatran were numerically superior to. Sherwood, md, medical instructor durham va medical center structural interventional cardiology fellow duke university medical center duke clinical. Percutaneous left atrial appendage closure vs warfarin for. Both had noninferiority to warfarin as primary endpoint. Outcomes of discontinuing rivaroxaban compared with warfarin. Stroke and embolism trial in atrial fibrillation rocket af trial, the efficacy and safety of rivaroxaban, a novel, oral, direct factor xa inhibitor, was assessed for the prevention of stroke in patients with atrial fibrillation af and at moderate to high risk of stroke. New analyses of pointofcare monitoring in rocket af trial. Dec 07, 2015 known as rocket af, the trial results convinced the fda four years ago to approve xarelto for preventing strokes in people with atrial fibrillation, or abnormal heart rhythms. In the rocket af trial, researchers enrolled 14,264 patients diagnosed with nonvalvular atrial fibrillation with a mean chads 2 score of 3. The appraisal committee considered that the itt population included people who had either had no treatment or switched treatment during the trial, and concluded that the estimates derived from the.
The methodology and results of the rocket af trial have been described in detail. Advances in stroke prevention in atrial fibrillation. An efficacy and safety study of rivaroxaban with warfarin for. Effectiveness and safety of rivaroxaban and warfarin for prevention. Rocket af capped chads2 2 early in the trial unless a patient scored two points by having a prior stroketia. The trial, known as the rocket af trial was published in the new england journal of medicine nejm in 2011. For example in the rely, the pradaxa pivotal trial, 1. The absolute fatality rate from gi bleeding was low and similar in both treatment arms. The rocket af trial showed that among patients with nonvalvular af, rivaroxaban was noninferior to warfarin in preventing stroke or. Apixaban is a novel oral direct factor xa inhibitor that. Efficacy and safety of apixaban, dabigatran, rivaroxaban.
Stroke and embolism trial in atrial fibrillation clinicaltrials. The rocket af trial was designed as double blind, double dummy trial comparing rivaroxaban 20mg or 15mg once aday with warfarin target inr of 2. Food and drug administration fdas decision to recall the alere inratio and inratio2 ptinr monitor device used in the trial. Selective serotonin reuptake inhibitors and bleeding risk in. Clinical characteristics and outcomes with rivaroxaban vs. Specifically, the medical community has been raising serious concerns. The original study determined that among patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the. Atrial fibrillation rocket af is pro vided in the supplementary appendix, available at. Rocket af trial suggests that digoxin increases risk of death. In addition, subjects must have medical evidence of atrial fibrillation within 1 year before and at least one day before the qualifying ecg evidence.
Evidence for the efficacy of rivaroxaban came from the warfarincontrolled rocket af rocket trial, which also contributed much of the safety data in the application see sec. Nov 22, 20 dallas in patients with nonvalvular atrial fibrillation, outcomes after a major bleeding event were similar for patients assigned rivaroxaban and those assigned warfarin, according to a new. Researchers defined worsening kidney function as a decline in creatinine clearance of more than 20% from baseline. The new engl and journal of medicine 884 n engl j med 365. The composite of major bleeding and nonmajor clinically relevant bleeding events, evaluated in the safety population ontreatment analysis, occurred in 8 patients in the rivaroxaban group 18. Rivaroxaban for the prevention of stroke and systemic. It examines the efficacy and safety of aspirin versus placebo and either nonvitamin k antagonist vka apixaban or vka oral antagonist warfarin, for example and a p2y12 inhibitor like clopidogrel. Prevention of stroke and embolism trial in atrial fibrillation rocket af trial. The true prevalence of af is difficult to assess, as a significant proportion of patients will be asymptomatic or have subclinical disease. Apixaban eliquis factor xa inhibitor, doses 5 and 2. Sep 16, 2019 february 3, 2016 the results of a reanalysis of the rocket af trial were published recently in the new england journal of medicine. After an inrmonitoring device used in the rocket af trial was recalled by the fda because of possible inaccuracies in inr readings under certain conditions, a post hoc reanalysis of the trial data. Rocket af included 14 264 patients with nonvalvular atrial fibrillation af.
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation. The rocket af trial rivaroxaban once daily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation is summarized in. Fda ignores faulty data in approving xarelto drug safety news. Time in therapeutic range ttr inr data inr range warfarin median 25th, 75th rocket af. In october 2015, the rocket af executive committee initiated a reanalysis of the rocket af trial upon learning of the u. Ascendhf, rocketaf, gravitas, basket prove, define and more uncategorized the aha has published the list of latebreaking clinical trials to be presented at scientific sessions in november. In summary, rivaroxaban was shown to be noninferior to warfarin in preventing stroke and systemic embolism hr 0. There are additional drug interactions in which doacs should be avoided. Rivaroxaban xarelto factor xa inhibitor, doses 20 and 15 mg qd, pivotal trial. Sep 29, 2016 rocket af investigators seek to calm concerns about trial reliability december, 2015 new questions raised about rocket af, pivotal xarelto trial chaired by califf november 30, 2015 last. Results from the powder af multicentre randomized trial. As announced previously, the rocket af executive committee initiated a reanalysis of the rocket af trial in october 2015, immediately after learning of the u.
Dabigatran pradaxa direct thrombin inhibitor, doses 150 and 110 mg bid, pivotal trial. In the rocket af trial, rivaroxaban increased gi bleeding compared with warfarin. Rocket af rivaroxaban meets primary end point the first oral xa is noninferior to warfarin in af 2. Pulmonary vein isolation with versus without continued antiarrhythmic drug treatment in subjects with recurrent atrial fibrillation. Background rivaroxaban bay 597939 is an oral anticoagulant invented and manufactured by bayer. Rocket af compared rivaroxaban with warfarin in patients with atrial fibrillation. Strokes follow xarelto to warfarin switch medpage today. Comparative efficacy and safety of new oral anticoagulants. Percutaneous left atrial appendage closure for stroke.
The rationale and design of the rocket af study have been published. Hospitalizations in patients with atrial fibrillation. Nov 27, 2006 factors associated with major bleeding events. Backgroundvitamin k antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. J rocket af was a prospective, randomized, doubleblind, phase iii trial. Note that the rocket af trial found an increased risk of stroke after rivaroxaban was discontinued during the transition to warfarin in patients with nonvalvular atrial fibrillation. The study compared the performance of xarelto to that of warfarin, the standard treatment for nearly seven decades. Sep 02, 2014 the rocket af trial was a doubleblind trial conducted in 14 171 patients with nonvalvular af who were at increased risk of stroke. Late in 2011, rivaroxaban became the first factor xa inhibitor to receive regulatory approval for the prevention of stroke in patients with atrial fibrillation af, based largely on the results of the phase iii rocket af rivaroxaban oncedaily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation trial. The goal of the trial was to evaluate treatment with the oral direct factor xa inhibitor rivaroxaban compared with warfarin among patients with nonvalvular atrial fibrillation af. Pointofcare warfarin monitoring in the rocket af trial nejm.
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation. New posthoc analyses of rocket af confirm the main results of the controversial trial, according to a paper published in the new england journal of medicine. The augustus trial studies apixaban safety in patients with atrial fibrillation and acute coronary syndrome andor percutaneous intervention. Although effective, oral anticoagulation with warfarin to prevent stroke in patients with atrial fibrillation has limitations.
Rocket af trial rivaroxaban oncedaily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation, rechecks averaged 8 days in north america for an inr rocket af trial have been described previously. Correspondence from the new england journal of medicine pointofcare warfarin monitoring in the rocket af trial. Ehra issues guide for new afib drugs medpage today. Sep 01, 2015 the twoyear data, presented at esc, found the rates and patterns of major bleeding were generally consistent with the phase 3 rocket af trial. Medpage today, a ce and cme accredited medical news service, provides free continuing education to healthcare professionals in addition to the latest news. Primary and key secondary results from the rocket af trial. Time in the therapeutic range for patients taking warfarin. A number of secondary analyses of the rocket af trial detailing the use, safety and efficacy of rivaroxa. It compared rivaroxaban with the older anticlotting drug warfarin for preventing strokes in patients with irregular heartbeat nonvalvular atrial fibrillation. Becker, duke clinical research institute, duke university medical center, durham, nc. A total of 279 776 patients diagnosed with af international classi. Our results further illustrate the need for minimizing modifiable risk factors for gi bleeding in patients on oral anticoagulation.
789 907 358 1089 403 1516 868 283 183 45 177 305 608 924 1405 81 1151 1377 1387 1430 714 186 544 237 1367 974 1239 1182 975 117 1455 126 682 166 1232